mRNA |
Gefitinib |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.7 |
mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.7 |
mRNA |
NPC-26 |
CTRPv2 |
pan-cancer |
AAC |
-0.017 |
0.7 |
mRNA |
EX-527 |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.7 |
mRNA |
BRD-K16130065 |
CTRPv2 |
pan-cancer |
AAC |
0.034 |
0.7 |
mRNA |
BRD-K16147474 |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.7 |
mRNA |
S-Trityl-L-cysteine |
FIMM |
pan-cancer |
AAC |
-0.087 |
0.7 |
mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.015 |
0.7 |
mRNA |
tivozanib |
GDSC1000 |
pan-cancer |
AAC |
-0.015 |
0.7 |
mRNA |
BRD-K99584050 |
CTRPv2 |
pan-cancer |
AAC |
-0.024 |
0.7 |